Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

How CGMs are Riding the GLP-1 Wave to Transform Metabolic Health

4 August 2026 · By · Wire by Fusion42

Published

4 August 2026

Topic

opportunities

◆ Sectors

Digital HealthMedtechHealthtech Infrastructure

◆ Source

Read at idtechex.com →

◆ Verified

Fusion42 · 4 August 2026 · Fusion42 review

Continuous glucose monitors (CGMs) are increasingly integrated with the surge in GLP-1 based therapies, transforming metabolic health management by providing real-time feedback and personalised data to optimise treatment outcomes.

This Wire brief sits within Fusion42's coverage of Digital Health, Medtech and Healthtech Infrastructure.

◆ ◆ The Wire takeaway

You can tie your digital health product to emerging metabolic therapies through continuous glucose monitoring to unlock personalised health optimisation and new patient engagement routes.

◆ Coverage

1 source · 4 Aug 2026

◆ Related on Wire

◆ Topics

Digital HealthMedtechHealthtech Infrastructurecgmsglp-1metabolic-healthdigital-healththerapies